Skip to main content
HYUNDAI BIOSCIENCE CO., LTD. logo

HYUNDAI BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 048410 ISIN · KR7048410005 KO Professional, scientific and technical activities
Open in API
Filings indexed 288 across all filing types
Latest filing 2025-07-18 Director's Dealing
Country KR South Korea
Listing KO 048410

About HYUNDAI BIOSCIENCE CO., LTD.

http://www.hyundaibioscience.com/eindex…

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). This type of filing is a mandatory disclosure of changes in share ownership by major shareholders or insiders. In the provided taxonomy, 'Director's Dealing' (DIRS) is the category for reports of share transactions by company directors, executives, and major shareholders (insiders).
2025-07-18 Korean
[기재정정]주주총회소집결의 (임시주주총회)
AGM Information Classification · 98% confidence The document is a formal notice regarding the convocation of an Extraordinary General Meeting (EGM) for Hyundai Bio. It details the agenda items (appointment of auditors, director compensation, stock options) and provides specific meeting logistics. This type of document, which provides information to shareholders regarding upcoming meetings and voting items, is classified as a Proxy Solicitation & Information Statement (PSI).
2025-07-17 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting' (임시주주총회소집공고) issued by Hyundai Bioscience. It contains the agenda for the meeting, including the appointment of an auditor, approval of director/auditor compensation, and the granting of stock options. It also provides detailed information for shareholders regarding electronic voting and management references. This document is a proxy statement/notice sent to shareholders to solicit votes for an upcoming meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2025-07-17 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for an upcoming general meeting. It contains details about the meeting agenda, director/auditor candidates, and compensation limits. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2025-07-17 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and contractual obligations (such as stock collateral agreements) of a major shareholder (CnPharm Co., Ltd.) in Hyundai Bioscience. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-07-10 Korean
주권매매거래정지 (무상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a short regulatory notice regarding the suspension of stock trading for Hyundai Bioscience due to a bonus issue (무상증자). It cites specific KOSDAQ market regulations and provides the duration of the suspension. Since it is a regulatory announcement regarding trading status and does not fit into specific categories like share issuance or financial reporting, it is classified as a general regulatory filing.
2025-07-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.